Research

This is a great resource for newly-diagnosed EGFR lung cancer patients to learn from experts in this field about the disease and treatments available. Read more.

*May 2021* The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered and improved the therapeutic landscape of non-small cell lung cancer (NSCLC). ICIs confer a durable response in a subset of patients; however, their therapeutic role in oncogene-driven NSCLC remains unclear,…

*May 2021* Dr. Heather Wakelee joins GRACE to discuss treatment options for a metastatic non small cell lung cancer diagnosis. Listen here.

*April 2021* MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. Nevertheless, acquired resistance mechanisms to combined EGFR and MET inhibition are poorly understood. In this study, we investigated the mechanisms of acquired resistance…

*May 2021* The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation after progression on an EGFR tyrosine kinase inhibitor (TKI), according to results from a phase 1B/2 study…

*May 2021* The U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.)…

*June 2021* This webinar focuses on necessary testing, common mechanisms of EGFR-dependent resistance, and possible treatment strategies. Dr. Josh Bauml and Dr. Melina Marmarelis, both from the University of Pennsylvania provide their expertise. Watch it here.

*April 2021* The FDA has granted a priority review designation to a new drug application (NDA) for mobocertinib (TAK-788) for the treatment of adult patients with EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer (NSCLC), as detected via an FDA-approved assay, who have received previous platinum-based chemotherapy.1 The designation is…

*April 2021* In this podcast, Drs. H. Jack West, Helena Yu, and David Spigel discuss the addition of SBRT to a systemic EGFR inhibitor TKI in EGFR positive NSCLC. Listen here.

*April 2021* In this podcast, Drs. H. Jack West, Helena Yu, and David Spigel discuss the addition of SBRT to a systemic EGFR inhibitor TKI in EGFR positive NSCLC. Listen here.